(Reuters) - Merck & Co Inc posted a higher-than-expected quarterly profit as one-time tax gains helped offset plunging sales of its former flagship product, Singulair, an asthma drug that began facing cheaper generics in August.
Reuters: Top News, Reuters
Fri, 10/26/2012 - 8:18am
(Reuters) - Merck & Co Inc posted a higher-than-expected quarterly profit as one-time tax gains helped offset plunging sales of its former flagship product, Singulair, an asthma drug that began facing cheaper generics in August.